IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of **DEAV2003/0072 US NP** 

Application No.: 10/779,439

Filed:

February 13, 2004

M

Title: Nitrogen-Substituted

Hexahydropyrazino[1,2-a]Pyrimidine-4,7-Dione Derivatives, Processes For Their Preparation and The Use As

**Medicaments** 

Examiner:

Art Unit:

1615

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September & 2005

Brian Pritchett Signature

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	7(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
		authorized.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0072 US NP

Please type a plus sign (+) inside this box
---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

1

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known **Application Number** 10/779,439 Filing Date 02-13-2004 **First Named Inventor** FLOHR, et. al. Group Art Unit 1615 **Examiner Name** Not Yet Assigned Attorney Docket Number DEAV2003/0072 - US - NP

Examiner Initials*	Cite No.1	U.S. Patent D Number	ocument Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		2002/0065284		CARPINO, et. al.	03-30-2001				
					-				
$\vdash$									
<b>—</b>			-		<del>                                     </del>				
$\vdash$			•						
					<del>                                     </del>				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Office	Foreign Patent Do  Number <sup>4</sup>	cument Kind ( (if kn		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		wo	01/16135			STASIAK, et. al.	03-08-2001		Τ
		wo	97/26265			NIELSEN, et. al.	07-24-1997		Τ
		wo	97/41097			LOHRAY, et. al.	11-06-1997		T
		wo	98/08871			KNUDSEN, et. al.	03-05-1998		
		wo	99/03861			NIELSEN, et. al.	01-28-1999		$\perp$
						<u> </u>			╁
									$oxed{oxed}$

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

1	
Please type a plus sign (+) inside this box ->	>

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Examiner

Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete if Known

 Application Number
 10/779,439

 Filling Date
 02-13-2004

 First Named Inventor
 FLOHR, et. al.

 Group Art Unit
 1615

 Examiner Name
 Not Yet Assigned

 Attorney Docket Number
 DEAV2003/0072 - US - NP

(use as many sheets as necessary)

Sheet 2 of 2

1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		:	KRCHNAK, V., et. al., Noninvasive Continuous Monitoring of Solid-Phase Peptide Synthesis by Acid-Base Indicator, Collect. Czech. Chem. Commun. Vol.53, (1988) pp. 2542-2548			
			TYLE, P., et. al., Iontophoretic Devices for Drug Delivery, Pharmaceutical Research, 1986, Vol.3, No.6, 318-326	·		
			VOJKOVSKY, T., et. al., Solid-Phase Synthesis of Heterocycles Containing an 1-Acyl-3-oxopiperazine Skeleton, J. Org. Chem.; 63; 1998; pp. 3162-3163.			
				-		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.